source
- Avere Therapeutics to go public via reverse merger, secures $320M to advance long-acting psoriasis pillAvere Therapeutics, a privately held immunology drug developer, announced a plan to become a public company through a reverse merger with NextCure. The transaction includes $320 million in new cap…
- Biogen's tau-targeting Alzheimer's drug shows cognitive slowing in mid-stage trialBiogen reported results from its mid-stage "Celia" trial testing the experimental tau-targeting antibody BIIB080 in patients with early Alzheimer's disease. The study compared three dose levels of…